54 related articles for article (PubMed ID: 2683991)
1. Evaluation of cisplatin dose intensity: current status and future prospects.
Gandara DR; Perez EA; Phillips WA; Lawrence HJ; DeGregorio M
Anticancer Res; 1989; 9(4):1121-8. PubMed ID: 2683991
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity.
Gandara DR; Perez EA; Weibe V; De Gregorio MW
Semin Oncol; 1991 Feb; 18(1 Suppl 3):49-55. PubMed ID: 1848372
[TBL] [Abstract][Full Text] [Related]
3. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
[TBL] [Abstract][Full Text] [Related]
5. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer.
Bunn PA; Kelly K
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-144-S12-148. PubMed ID: 9331140
[TBL] [Abstract][Full Text] [Related]
7. [Importance of platinum dose intensity in treatment of epithelial ovarian cancer. Austrian Study Group for Therapy of Ovarian Cancer].
Sevelda P; Kurz C; Obermair A; Vavra N; Breitenecker G; Czerwenka K; Dittrich C; Salzer H
Wien Klin Wochenschr; 1993; 105(24):732-6. PubMed ID: 8116312
[TBL] [Abstract][Full Text] [Related]
8. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
Laurie SA; Pfister DG; Kris MG; Tong WP; Chronowski G; Pisters KM; Heelan RT; Sirotnak FM
Clin Cancer Res; 2001 Mar; 7(3):501-9. PubMed ID: 11297240
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin.
Rowinsky EK; Jiroutek M; Bonomi P; Johnson D; Baker SD
Clin Cancer Res; 1999 Apr; 5(4):767-74. PubMed ID: 10213211
[TBL] [Abstract][Full Text] [Related]
11. [Pilot study of dose intensive weekly chemotherapy followed by cisplatin plus etoposide with concurrent thoracic irradiation for limited-disease small-cell lung cancer. West Japan Thoracic Oncology Group].
Isobe T; Fukuoka M; Negoro S; Sugiura T; Kawahara M; Kudoh S; Araki J; Nakagawa K; Yokozaki M; Yamakido M; Ariyoshi Y
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1091-6. PubMed ID: 10945001
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support.
Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; Gonin R; McCauley M; Mazanet R; Schnipper L; Frei E
Bone Marrow Transplant; 1995 Mar; 15(3):373-9. PubMed ID: 7599561
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin dose intensity.
Ozols RF
Semin Oncol; 1989 Aug; 16(4 Suppl 6):22-30. PubMed ID: 2669135
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate.
Gandara DR; Wiebe VJ; Perez EA; Makuch RW; DeGregorio MW
Crit Rev Oncol Hematol; 1990; 10(4):353-65. PubMed ID: 2177606
[TBL] [Abstract][Full Text] [Related]
15. Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens.
Von Hoff DD; Clark GM; Weiss GR; Marshall MH; Buchok JB; Knight WA; LeMaistre CF
J Clin Oncol; 1986 Dec; 4(12):1827-34. PubMed ID: 2431110
[TBL] [Abstract][Full Text] [Related]
16. High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy: preliminary pharmacologic observations.
DeGregorio MW; Gandara DR; Holleran WM; Perez EA; King CC; Wold HG; Montine TJ; Borch RF
Cancer Chemother Pharmacol; 1989; 23(5):276-8. PubMed ID: 2539912
[TBL] [Abstract][Full Text] [Related]
17. Evolution of high-dose cisplatin.
Holleran WM; DeGregorio MW
Invest New Drugs; 1988 Jun; 6(2):135-42. PubMed ID: 3049431
[TBL] [Abstract][Full Text] [Related]
18. Biochemical modulation of cisplatin toxicity.
Borch RF; Markman M
Pharmacol Ther; 1989; 41(1-2):371-80. PubMed ID: 2652155
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin update.
Muggia FM
Semin Oncol; 1991 Feb; 18(1 Suppl 3):1-4. PubMed ID: 2003223
[No Abstract] [Full Text] [Related]
20. Cisplatin in the treatment of solid tumors: effect of dose and schedule.
Livingston RB
J Natl Cancer Inst; 1989 May; 81(10):724-5. PubMed ID: 2654403
[No Abstract] [Full Text] [Related]
[Next] [New Search]
